Autosomal dominant tubulointerstitial kidney disease (ADTKD)

Authors

  • Marco Quaglia Dipartimento di Medicina Traslazionale, Università del Piemonte Orientale, Novara
  • Michele Battista Dipartimento di Medicina Traslazionale, Università del Piemonte Orientale, Novara
  • Guido Merlotti Dipartimento di Medicina Traslazionale, Università del Piemonte Orientale, Novara
  • Martina Mazzariol Dipartimento di Medicina Traslazionale, Università del Piemonte Orientale, Novara
  • Vincenzo Cantaluppi Dipartimento di Medicina Traslazionale, Università del Piemonte Orientale, Novara

DOI:

https://doi.org/10.33393/gcnd.2017.681

Keywords:

Autosomal dominant tubulointerstitial kidney disease, Genetic analysis, Genetic mutations, Hepatocyte nuclear factor-1 β, Mucin-1, Renin, Uromodulin

Abstract

Autosomal Dominant Tubulointerstitial Kidney Diseases (ADTKD) are a group of autosomal dominant hereditary nephropathies which share a rather aspecific pathological picture of interstitial fibrosis and tubular atrophy (IFTA) and a slowly progressing tubulointerstitial clinical profile: end-stage renal disease (ESRD) generally occurs between 30 and 50 years. Four types of ADTKD have been described so far, each showing some peculiarities: hepatocyte nuclear factor-1 β (HNF1β) ADTKD, in which ADTKD can be associated with renal cysts and a wide spectrum of congenital abnormalities of kidney and urinary tract (CAKUT) and extra-renal manifestations (diabetes, liver enzyme alterations, genital malformations), uromodulin (UMOD) ADTKD, characterised by early onset of hyperuricemia and gout, mucin-1 (MUC-1) ADTKD, a recently discovered form which appears to be an isolated tubulointerstitial nephropathy, and renin (REN) ADTKD, which appears in childhood and is characterised by anemia and mild signs of hyporeninism. A better awareness is needed in order to perform genetic analysis whenever clinical setting is compatible with this nephropathy. A timely diagnosis can have an important impact on both the patient and his family members in terms of therapy and prognosis, also at the prospect of renal transplant.